University Health Network-Princess Margaret Cancer Centre
Welcome,         Profile    Billing    Logout  
 3 Trials 
25 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Spreafico, Anna
TRANSPARENT, NCT06457503: A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer

Recruiting
4
100
Canada, US
Toripalimab, JS001, TAB-001, CHS-007, Cisplatin, Gemcitabine, Carboplatin
Coherus Biosciences, Inc.
Nasopharyngeal Cancer Recurrent
12/27
12/27
JADE, NCT06256588: A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

Recruiting
3
864
Europe, Canada, Japan, US, RoW
Dostarlimab, Placebo
GlaxoSmithKline
Neoplasms, Head and Neck
05/28
07/29
MET4-IO, NCT03686202: Feasibility Study of Microbial Ecosystem Therapeutics (MET-4) to Evaluate Effects of Fecal Microbiome in Patients on ImmunOtherapy

Active, not recruiting
2/3
65
Canada
MET-4
University Health Network, Toronto, NuBiyota
All Solid Tumors
12/24
12/25
PROMOTE-HN, NCT05743777: PembROlizumab With or Without Microbial EcOsystem ThErapeutic 4 (MET4) in Advanced Head and Neck Squamous Cell Carcinoma

Withdrawn
2
100
NA
Pembrolizumab, MET-4, Placebo
Canadian Cancer Trials Group, NuBiyota
Advanced Head and Neck Squamous Cell Carcinoma
05/23
05/23
BEAVER, NCT03839342: Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations

Active, not recruiting
2
26
Canada
Binimetinib, Encorafenib
University Health Network, Toronto
Solid Tumor
12/25
12/25
ClearMe, NCT06319196: Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma

Recruiting
2
54
Canada
Opdualag, BMS-986213, Nivolumab
University Health Network, Toronto
Cutaneous Melanoma, Melanoma Stage IV, Mucosal Melanoma
02/27
02/30
NCT03410615: Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC

Active, not recruiting
2
129
Europe, Canada
Radiation, Cisplatin, Durvalumab, Tremelimumab
Canadian Cancer Trials Group, AstraZeneca
Oropharyngeal Squamous Cell Carcinoma
01/26
07/26
COBRA, NCT05220098: First-in-Human Study of TAK-280 in Participants With Solid Tumors

Recruiting
1/2
182
Europe, Canada, US, RoW
TAK-280
Takeda, Takeda Development Center Americas, Inc.
Unresectable Locally Advanced or Metastatic Cancer
02/25
07/26
NCT04672434: Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies

Completed
1
48
Canada, US
Sym021, Anti-PD-1, Sym024
Symphogen A/S
Metastatic Cancer, Solid Tumor
11/24
11/24
NCI10208, NCT03816358: Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer

Active, not recruiting
1
74
Canada, US
Anetumab Ravtansine, BAY 94-9343, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemcitabine HCI, Gemzar, LY 188011, LY-188011, LY188011, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS 734016, BMS-734016, BMS734016, Ipilimumab Biosimilar CS1002, MDX 010, MDX-010, MDX-CTLA4, MDX010, Yervoy, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo
National Cancer Institute (NCI)
Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
01/25
01/25
AIM-NIVO, NCT03816345: Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer

Recruiting
1
300
Canada, US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo
National Cancer Institute (NCI)
Autoimmune Disease, Crohn Disease, Dermatomyositis, Hematopoietic and Lymphoid Cell Neoplasm, Inflammatory Bowel Disease, Malignant Solid Neoplasm, Multiple Sclerosis, Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Sjogren Syndrome, Systemic Lupus Erythematosus, Systemic Scleroderma, Ulcerative Colitis
08/26
08/26
SGNPDL1V-001, NCT05208762: A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

Recruiting
1
438
Europe, Canada, US
PF-08046054, SGN-PDL1V, pembrolizumab, Keytruda
Seagen Inc.
Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Esophageal Squamous Cell Carcinoma, Ovarian Neoplasms, Melanoma, Triple Negative Breast Neoplasms, Gastric Cancer
07/25
12/27
ROMA LA-OPSCC2, NCT03838601: Role of Microbiome as a Biomarkers in Locoregionally-Advanced Oropharyngeal Squamous Cell Carcinoma 2

Active, not recruiting
N/A
30
Canada
MET-4
University Health Network, Toronto, NuBiyota
Head and Neck Squamous Cell Carcinoma
01/25
03/25
IRIS, NCT04243720 / 2011-004908-37: Immune Resistance Interrogation Study

Recruiting
N/A
100
Canada
University Health Network, Toronto
Cancer, Solid Tumor, Metastatic Cancer, Immune Resistance
02/25
02/25
INSPECT-IO, NCT04107311: Prospective Analysis of Intestinal Microbiome and Autoimmune Panels as Predictors of Toxicity in ImmunOncology Patients

Recruiting
N/A
120
Canada
University Health Network, Toronto
Solid Tumor
03/25
03/25
CAN-IMPACT-IO, NCT06630273: Canadian Initiative to Measure, Predict and Assess Cancer Treatment Outcomes in Patients Treated With Immuno-Oncotherapeutics

Not yet recruiting
N/A
120
NA
Canadian Cancer Trials Group
Carcinoma
12/27
12/27
GEMS-001, NCT02069730: A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes

Active, not recruiting
N/A
114
Canada
Selinexor, KPT-330, EGFR or HER2 Inhibitor, Matched treatment, FGFR Inhibitor, C-KIT Inhibitor, Matched Treatment, Anti-androgen, NOTCH Inhibitor, MEK or PI3K Inhibitor
University Health Network, Toronto
Salivary Gland Cancer, Metastatic, Advanced, Recurrent
12/26
12/27
Almeida, John de
SELECT, NCT05451004: SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer

Recruiting
3
510
Canada, US
Lymphatic Mapping with SPECT-CT, Ipsilateral and Contralateral Neck
Canadian Cancer Trials Group, Alliance for Clinical Trials in Oncology, Eastern Cooperative Oncology Group, NRG Oncology, SWOG Cancer Research Network
Oropharyngeal Cancer
08/30
08/31
NRG-HN006, NCT04333537: Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer

Recruiting
2/3
618
Canada, US
Computed Tomography (CT), CAT, CAT scan, Computed Tomography, computerized axial tomography, Computerized Tomography, CT, CT scan, tomography, Imaging Agent, Image Enhancement Agent, Neck Dissection, Planar Imaging, Sentinel Lymph Node Biopsy, Sentinel Node Biopsy, Sentinel node biopsy alone, SLNB, SNB, Single Photon Emission Computed Tomography, Medical Imaging, Single Photon Emission Computed Tomography, Single Photon Emission Tomography, single-photon emission computed tomography, SPECT, SPECT imaging, SPECT SCAN, SPET, tomography, emission computed, single photon, Tomography, Emission-Computed, Single-Photon
NRG Oncology, National Cancer Institute (NCI)
Buccal Mucosa Squamous Cell Carcinoma, Floor of Mouth Squamous Cell Carcinoma, Gingival Squamous Cell Carcinoma, Hard Palate Squamous Cell Carcinoma, Lip Squamous Cell Carcinoma, Lower Alveolar Ridge Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma, Retromolar Trigone Squamous Cell Carcinoma, Stage I Lip and Oral Cavity Cancer AJCC v8, Stage II Lip and Oral Cavity Cancer AJCC v8, Tongue Squamous Cell Carcinoma, Upper Alveolar Ridge Squamous Cell Carcinoma
05/31
05/36
FIND, NCT03281499: Transoral Robotic Surgery and Tailored Radiotherapy in Unknown Primary and Small Squamous Cell Head and Neck Cancer

Completed
N/A
22
Canada
da Vinci Surgical System Model IS4000, tailored radiotherapy regimen
University Health Network, Toronto
Head and Neck Squamous Cell Carcinoma
07/22
07/22
NCT05055206: Study of Lymphatic Drainage Mapping in Oropharyngeal Cancers

Completed
N/A
12
Canada
SPECT-CT
University Health Network, Toronto
Oropharynx Cancer
10/23
10/23
HNC-TACTIC, NCT05117775: Towards A Better Paradigm for Head and Neck Cancer Treatment Applying Artificial Intelligence. .

Recruiting
N/A
10000
Europe
No intervention - Just description and predictive models
Savana Research, Head and Neck Cancer International Group (HNCIG)
Head and Neck Cancer
02/24
12/24
Hosni, Ali
SELECT, NCT05451004: SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer

Recruiting
3
510
Canada, US
Lymphatic Mapping with SPECT-CT, Ipsilateral and Contralateral Neck
Canadian Cancer Trials Group, Alliance for Clinical Trials in Oncology, Eastern Cooperative Oncology Group, NRG Oncology, SWOG Cancer Research Network
Oropharyngeal Cancer
08/30
08/31
MAESTRO, NCT06050707: MR-Adaptive Radiation Therapy for Anal Cancer With EScalated-Treatment in a Risk-Optimized Approach

Recruiting
2
80
Canada, US, RoW
Radiotherapy - Low risk group, Radiotherapy - Standard risk group, Radiotherapy - Intermediate risk group, Radiotherapy - High risk group
University Health Network, Toronto, Medical College of Wisconsin Cancer Center, Allegheny Health Network, Austin Health
Anal Squamous Cell Carcinoma
09/28
09/28
NCT04395469: FAZA PET/MRI Pancreas

Active, not recruiting
N/A
20
Canada
18F-FAZA
University Health Network, Toronto
Pancreatic Adenocarcinoma Non-resectable, Locally Advanced Pancreatic Adenocarcinoma, Unresectable Pancreatic Cancer
03/25
03/25
Chen, Tongtong
No trials found

Download Options